Children receiving intermediate, high dose MTX experience poor CINV control
the ONA take:
Children with cancer receiving methotrexate had a poor complete chemotherapy-induced nausea and vomiting (CINV) rate, both in the acute and delayed phases, according to a new study published in the journal Supportive Care in Cancer.
For the prospective study, 30 children received intermediate-dose (ID-MTX: >1 to <12/g/m2/dose) or high-dose methotrexate (HD-MTX: ≥12 g/m2/dose). CINV prophylaxis was provided to pediatric patients at the discretion of the clinician.
Researchers documented antiemetic administration, nausea severity, and emetic episodes during the acute phase (for 24 hours from the start of the methotrexate infusion) and the delayed phase (for up to a further 168 hours).
Researchers found that CINV prophylaxis received ondansetron or granisetron plus dexamethasone or nabilone. Results showed that among the 10 patients that received HD-MTX, 0% achieved complete control during the acute phase and 30% experienced complete control in the delayed phase.
Among the 20 patients that received ID-MTX, the complete control rates were 20% and 5% in the acute and delayed phase, respectively.
The findings confirm the classification of HD-MTX as highly emetogenic chemotherapy and suggest that ID-be reclassified as highly emetogenic chemotherapy, as well.
Children with cancer receiving methotrexate had a poor complete chemotherapy-induced nausea and vomiting (CINV) rate.
- Novel Blood Test Detects Cancer, Locates Tumor Without Invasive Procedures
- Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer
- Shorter Treatment of Breast Cancer with Trastuzumab May Lead to Improved Results
- Colorectal Cancer Rates Increased Sharply Among Generation X and Millennials
- Pneumonia Associated With Common Cold May Cause Fatal Illness in Stem Cell Transplant Recipients
- Early Palliative Care Reduced ICU Use in Patients With Advanced Cancer
- Ginger Extract Raises Antioxidant Levels in Patients Undergoing Chemotherapy
- Nurse Navigators Improve Physician Engagement in Pretreatment Discussions
- Screening Increases Early Palliative Care, Reduces Aggressive EOL Measures
- Antiperspirants/Deodorants and Breast Cancer (Fact Sheet)
- Genetic Similarity to BRCA1/BRCA2 Mutations May Impact Treatment Options
- Evidenced-Based Radiation Treatment Tied to Cost Savings in Early Stage Breast Cancer
- Genome Sequencing Explains Resistance to CTLA-4 and PD-1 Inhibitors in Metastatic Melanoma
- Lifestyle Choices Have Greater Influence on Colon and Rectal Cancer Risk
- Kidney Cancer Metastases in Lung May Hide Undiagnosed Primary Lung Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|